Premium
Myeloproliferative disorder therapy: assessment and management of adverse events—a dermatologist's perspective
Author(s) -
Soutou Boutros,
Aractingi Sélim
Publication year - 2009
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.912
Subject(s) - perspective (graphical) , medicine , dermatology , adverse effect , intensive care medicine , computer science , artificial intelligence
Abstract Development of cutaneous manifestations in patients with myeloproliferative disorders can be either due to the course of the disease itself or induced by some of the treatments given. The cutaneous manifestations may reveal an unknown haemopathy and/or indicate a poor prognosis. Some of these alter quality of life. Hydroxyurea has been shown to induce a variety of cutaneous adverse reactions ranging from benign effects such as hyperpigmentation to more severe leg ulcers and squamous cell carcinomas. Herein, we discuss the importance of undertaking regular physical examinations in order to identify and treat cutaneous manifestations early in their course. Copyright © 2009 John Wiley & Sons, Ltd.